Print

CeNes Pharmaceuticals (U.S.) (CEN.L) Starts Recruitment for Phase II trial of CNS 5161 for Cancer Pain  
9/12/2007 11:42:39 AM

LONDON (Thomson Financial) - CeNeS Pharmaceuticals PLC said it has started recruitment for a Phase II study of the potential new pain drug CNS 5161, which is being developed under a co-development deal with the ERGOMED Group.